News and Trends 17 Jan 2023 EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, says the first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What’s in store for biotech in 2023? Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […] January 11, 2023 - 14 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 2023 Editorial Calendar updated Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special editions are an opportunity to take a deeper look at topics of interest. It also allows us to focus on some of the special awareness days – of which there are many – associated with health and the life sciences. […] January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Biomica raises $20M to advance microbiome-based therapeutics pipeline Biomica Ltd., a subsidiary of Evogene Ltd., has signed a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities. The financing round will enable Biomica to develop its pipeline of microbiome-based therapeutics. The company […] December 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 5 Dec 2022 Interview: why the recently approved fecal microbiome product is causing a rumble The news last week of the FDA approving Ferring Pharmaceuticals’ first fecal microbiome product, Rebyota, caused quite a stir in the field. The news was described as a huge step, a giant leap forward and simply fantastic. Paul Feurstadt is the director of non-inflammatory bowel disease research at the Medical Research Center of Connecticut. He also […] December 5, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2022 FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field The first fecal microbiota product, Rebyota, approved by the U.S. Food and Drug Administration (FDA) today has been hailed ‘fantastic news’ by those in the microbiome field. Ferring Pharmaceutical’s product is approved to stop Clostridiodes difficile infection (CDI) in people over 18 and to be given after they have completed an antibiotic treatment for the […] December 1, 2022 - 6 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 14 Nov 2022 MaaT Pharma: leading the charge in microbiome therapeutics The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business officer at the French biotech MaaT Pharma outlines the firm’s efforts to blaze a trail in clinical testing and manufacturing in the new field. The microbiome world recently made a regulatory step forward as Australia greenlit a stool transplant developed […] November 14, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 28 Oct 2022 Persephone Biosciences studies the microbiome in baby poop Disruption in the gut microbiome is linked to a wide range of health problems in newborn babies and patients with cancer. Persephone Biosciences is studying stool samples from these populations to devise bacterial treatments that improve gut health. Research into the gut microbiome has advanced a long way in the last decades. One major boost […] October 28, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 19 Oct 2022 Neobe Therapeutics breaks down tumor defenses with bacteria Many cancer patients cannot benefit from cancer immunotherapy because their tumors are protected from the immune system. Neobe Therapeutics’ bacterial therapy is designed to strip the tumors of their protective barriers. The immune system is very good at fighting tumors, and cancer immunotherapies are often able to supercharge our natural defenses to great effect. However, […] October 19, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Clinical Microbiomics acquires MS-Omics Clinical Microbiomics, a microbiome research company, has acquired MS-Omics, a metabolomics provider based in Denmark. Clinical Microbiomics works on clonal-level microbiome profiling. With the acquisition, Clinical Microbiomics adds expertise in metabolite profiling from MS-Omics to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease. […] October 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants. Organ damage occurs in up to 70% of patients in the first few months following stem cell transplant. The reasons for this potentially life-threatening reaction have long been the subject of scientific research. Now, researchers led by Georg Stary […] October 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 License granted to EnteroBiotix for manufacture of microbiome product candidates Microbiome therapeutics company, EnteroBiotix Limited has been granted a manufacturer’s license for a GMP manufacturing facility for Investigational Medicinal Products (IMP) to make microbiome product candidates for clinical trials. It was given by the Medicines and Healthcare Products Regulatory Agency (MHRA) and also incorporates an in-house QC hub and analytical department. EnteroBiotix’s manufacturing capabilities include […] October 11, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email